Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Erasca (NASDAQ:ERAS) through any online brokerage.
Other companies in Erasca’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Erasca has a consensus price target of $14.21.
The stock price for Erasca (NASDAQ: ERAS) is $15.5008 last updated October 8, 2026 at 7:56 PM EDT.
There are no upcoming dividends for Erasca.
Erasca does not have any upcoming earnings scheduled.
There is no upcoming split for Erasca.
Erasca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.